Date: 2010-11-01
Type of information: Initiation of the trial
phase: 2
Announcement: initiation of the trial
Company: Eli Lilly (USA - IN)
Product: galunisertib (LY2157299)
Action
mechanism: kinase inhibitor. Galunisertib (LY2157299) is a TGF beta R1 kinase inhibitor that in vitro selectively blocks TGF beta signaling. TGF beta promotes tumors growth, suppresses the immune system, and increases the ability of tumors to spread in the body. Immune function is suppressed in cancer patients, and TGF beta worsens immunosuppression by enhancing the activity of immune cells called T regulatory cells. TGF beta also reduces immune proteins, further decreasing immune activity in patients Galunisertib is currently under investigation as an oral treatment for advanced/metastatic malignancies, including Phase 2 evaluation in hepatocellular carcinoma, myelodysplastic syndromes (MDS), glioblastoma, and pancreatic cancer.
Disease: hepatocellular carcinoma
Therapeutic area: Cancer - Oncology
Country: Australia, France, Germany, Italy, New Zealand, Spain, Switzerland, USA
Trial
details: The purpose of this study is to estimate the median time to progression in participants with hepatocellular carcinoma (HCC) when treated with LY2157299 with or without sorafenib. (NCT01246986)
Latest
news: * On November 1, 2010, a Phase 1b/2a trial sponsored by Eli Lilly was published on the NIH website ClinicalTrials.gov galunisertib (LY2157299) and is currently ongoing.
